Management ChangeApr 23, 2026, 04:43 PM
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board
AI Summary
Vaxart, Inc. announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings over 35 years of biopharmaceutical experience, including leading clinical development programs that resulted in eight FDA product approvals. His expertise in drug development and navigating regulatory paths is expected to strengthen the Board as Vaxart advances its oral vaccine platform.
Key Highlights
- Dr. James Breitmeyer appointed to Vaxart's Board of Directors.
- Brings over 35 years of biopharmaceutical experience.
- Led clinical development for eight FDA product approvals.
- Previously President of Bavarian Nordic, Inc., with vaccine expertise.
Price Impact
More from VXRT